Active	Status	Sponsor type	Region	Phase	Filter
9 Active 11 Inactive 20 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lewis, Gary F
PALISADE, NCT05089084 / 2021-003680-10: Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)	Active, not recruiting	3	75	Europe, Canada, Japan, US, RoW	Plozasiran, ARO-APOC3, Placebo	Arrowhead Pharmaceuticals	Familial Chylomicronemia	04/24	04/26
VOICE, NCT04648020 / 2021-000999-11: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.	Terminated	2b	190	Europe, US	Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet	Monopar Therapeutics, Monopar Therapeutics Inc.	Chemoradiotherapy-Induced Severe Oral Mucositis	05/23	05/23
NCT05323253: A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma	Recruiting	N/A	86	Canada, US, RoW	DaRT seeds, DaRT	Alpha Tau Medical LTD.	Recurrent Squamous Cell Carcinoma	12/25	12/25